JAK2 and melanoma: The acquired resistance to anti-PD-1 immunotherapy in melanoma tumors was found to be related to several mutations in genes encoding interferon receptor-associated Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2), which could result in the insensitivity of tumor cells to IFN-γ.